Ali M. Saeed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali M. Saeed has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Favorov
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
17 shared publications - Archana Balan
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
17 shared publications - Daria A. Gaykalova
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA
17 shared publications - Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
17 shared publications - Elizabeth M. Jaffee
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
17 shared publications - Jessica Gore
Department of Otorhinolaryngology-Head and Neck Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland
17 shared publications
Latest Publications
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S1. TCGA cancer study abbreviations and names.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S1. TCGA cancer study abbreviations and names.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Aberrant alternative splicing can generate neoantigens, which can themselves stimulate immune responses and surveillance. Previous methods for quantifying splicing-derived neoantigens are limited by independent references and potential batch effects. Here, we introduce SpliceMutr, a bioinformatics approach and pipeline for identifying splicing-derived neoantigens from tumor and normal data. SpliceMutr facilitates the identification of tumor-specific antigenic splice variants, predicts MHC-binding affinity, and estimates splicing antigenicity scores per gene. By applying this tool to transcriptomic data from The Cancer Genome Atlas, we generate splicing-derived neoantigens and neoantigenicity scores per sample and across all cancer types and find numerous correlations between splicing antigenicity and well-established biomarkers of antitumor immunity. Notably, carriers of mutations within splicing machinery genes have higher splicing antigenicity, which provides support for our approach. Further analysis of splicing antigenicity in cohorts of patients with melanoma treated with mono- or combined immune checkpoint inhibition suggests that the abundance of splicing antigens is reduced post-treatment from baseline in patients who progress. We also observe increased splicing antigenicity in responders to immunotherapy, which may relate to an increased capacity to mount an immune response to splicing-derived antigens. We find the splicing antigenicity to be higher in tumor samples when compared with normal, that mutations in the splicing machinery result in increased splicing antigenicity in some cancers, and higher splicing antigenicity is associated with positive response to immune checkpoint inhibitor therapies. Furthermore, this new computational pipeline provides novel analytical capabilities for splicing antigenicity and is openly available for further immuno-oncology analysis.Significance:SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load of some The Cancer Genome Atlas cancer subtypes. Future studies of the relationship between splicing antigenicity and immune checkpoint inhibitor response pan-cancer are essential to establish the interplay between antigen heterogeneity and immunotherapy regimen on patient response.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Aberrant alternative splicing can generate neoantigens, which can themselves stimulate immune responses and surveillance. Previous methods for quantifying splicing-derived neoantigens are limited by independent references and potential batch effects. Here, we introduce SpliceMutr, a bioinformatics approach and pipeline for identifying splicing-derived neoantigens from tumor and normal data. SpliceMutr facilitates the identification of tumor-specific antigenic splice variants, predicts MHC-binding affinity, and estimates splicing antigenicity scores per gene. By applying this tool to transcriptomic data from The Cancer Genome Atlas, we generate splicing-derived neoantigens and neoantigenicity scores per sample and across all cancer types and find numerous correlations between splicing antigenicity and well-established biomarkers of antitumor immunity. Notably, carriers of mutations within splicing machinery genes have higher splicing antigenicity, which provides support for our approach. Further analysis of splicing antigenicity in cohorts of patients with melanoma treated with mono- or combined immune checkpoint inhibition suggests that the abundance of splicing antigens is reduced post-treatment from baseline in patients who progress. We also observe increased splicing antigenicity in responders to immunotherapy, which may relate to an increased capacity to mount an immune response to splicing-derived antigens. We find the splicing antigenicity to be higher in tumor samples when compared with normal, that mutations in the splicing machinery result in increased splicing antigenicity in some cancers, and higher splicing antigenicity is associated with positive response to immune checkpoint inhibitor therapies. Furthermore, this new computational pipeline provides novel analytical capabilities for splicing antigenicity and is openly available for further immuno-oncology analysis.Significance:SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load of some The Cancer Genome Atlas cancer subtypes. Future studies of the relationship between splicing antigenicity and immune checkpoint inhibitor response pan-cancer are essential to establish the interplay between antigen heterogeneity and immunotherapy regimen on patient response.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S1. TCGA cancer study abbreviations and names.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S1. TCGA cancer study abbreviations and names.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
The supplementary figures file
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
SpliceMutr pipeline. The SpliceMutr pipeline uses RNA-seq data from two groups of samples and evaluates the changes in SA between them. In this example, the alternative splicing analysis compares tumor and normal RNA-seq samples. The pipeline performs splicing-aware alignment, gene expression quantification, and HLA genotyping. The splicing-aware alignment splice junction counts are then input into LeafCutter to evaluate differential splice junction usage. The tumor-specific and normal-specific splice junctions undergo transcript formation, translation, and kmerization for MHCnuggets input through SpliceMutr, then are evaluated for genotype-specific MHC binders using MHCnuggets (22). MHC binders associated with normal-specific and tumor-specific peptides are then used to calculate a per-gene and sample SA metric dependent on the type of the sample. SAT(G) is calculated for tumor samples and SAN(G) is calculated for normal samples. SA, splicing antigenicity.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
SpliceMutr pipeline. The SpliceMutr pipeline uses RNA-seq data from two groups of samples and evaluates the changes in SA between them. In this example, the alternative splicing analysis compares tumor and normal RNA-seq samples. The pipeline performs splicing-aware alignment, gene expression quantification, and HLA genotyping. The splicing-aware alignment splice junction counts are then input into LeafCutter to evaluate differential splice junction usage. The tumor-specific and normal-specific splice junctions undergo transcript formation, translation, and kmerization for MHCnuggets input through SpliceMutr, then are evaluated for genotype-specific MHC binders using MHCnuggets (22). MHC binders associated with normal-specific and tumor-specific peptides are then used to calculate a per-gene and sample SA metric dependent on the type of the sample. SAT(G) is calculated for tumor samples and SAN(G) is calculated for normal samples. SA, splicing antigenicity.